The recent emergence of novel neoadjuvant and/or adjuvant therapies for early stage (I-IIIA)
non-small cell lung carcinoma (NSCLC), mainly tyrosine kinase inhibitors (TKIs) targeting …

The scenario of neoadjuvant and adjuvant settings in non-small cell lung cancer (NSCLC) is
rapidly evolving. As already happened for the advanced disease, also early stages have …

PURPOSE With increased adoption of next-generation sequencing, tailored therapy on the
basis of molecular status is being delivered for patients with early-stage resectable non …

Background Targeted and immunotherapies are currently moving toward early-stage
settings for patients with non-small cell lung cancer (NSCLC). Predictive biomarkers data …

Introduction Lung cancer remains one of the most commonly diagnosed malignancies
worldwide and the leading cause of cancer-related death. 1 Until the last decade, non-small …

The discovery of oncogenic driver mutations rendering non-small cell lung cancer (NSCLC)
targetable by small-molecule inhibitors, and the development of immunotherapies, have …

Historical, the non-small cell lung cancer (NSCLC) was as a united disease entity and the
chemotherapy to the metastatic cancer had limited results. Recent studies for the metastatic …

The management of advanced non-small cell lung cancer (NSCLC) has been revolutionized
in recent years with the introduction of biomarker-targeted molecular therapies and immune …

Precision medicine in non-small cell lung cancer (NSCLC) is a rapidly evolving area, with
the development of targeted therapies for advanced disease and concomitant molecular …

Nonadvanced non-small-cell lung cancer (NSCLC) has a poor long-term survival from
surgery or definitive radiation that is minimally improved with induction/adjuvant …